Cite
HARVARD Citation
Tita, C. et al. (2017). A Phase 2a dose‐escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS‐986231 in hospitalized patients with heart failure with reduced ejection fraction. European journal of heart failure. pp. 1321-1332. [Online].